Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions

Castelo-Branco, Luís; Morgan, Gilberto; Prelaj, Arsela; Scheffler, Matthias; Canhão, Helena; Meerbeeck, Jan P. van; Awada, Ahmad

doi:10.1016/j.esmoop.2022.100764

Cited by 4 publications

(2 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is difficult now to predict which patients will respond to a particular PD-1/PD-L1 inhibitor. Advancements in knowledge may provide for future research to be conducted and assess specific biomarkers that can predict and monitor a patient's cellular response to treatment [ 71 ]. Research is also still being done to analyze how a tumor's response to anti-PD-1/PD-L1 may correlate with the cancer's PD-L1 expression levels.…”

Section: Reviewmentioning

confidence: 99%

Immune Checkpoint Inhibitors: A Narrative Review on PD-1/PD-L1 Blockade Mechanism, Efficacy, and Safety Profile in Treating Malignancy

Benelli,

Brandon,

Hew

2024

Cureus

View full text Add to dashboard Cite

Checkpoint inhibitors have been implicated in the treatment of several cancers due to their ability to exploit the immune system's regulatory pathways. This article serves to emphasize the importance of these immunotherapeutic agents and provide further insight into their mechanisms, efficacies, and safety profiles. The main agents in question include programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1). Several literature sources were found to assess the use of these inhibitors in cancers involving the lung, breast, and skin. Several peer-reviewed systematic reviews and the outcomes of clinical trials are combined within this article to support the use and further investigation of these agents in treating neoplasms. Further research into these forms of therapy underscores the revolutionary advancement of oncological interventions, which is important given the rising incidence of neoplasms within populations.

show abstract

Section: Reviewmentioning

confidence: 99%

Immune Checkpoint Inhibitors: A Narrative Review on PD-1/PD-L1 Blockade Mechanism, Efficacy, and Safety Profile in Treating Malignancy

Benelli,

Brandon,

Hew

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…These inhibitors, such as antibodies against programmed cell death protein 1 (PD-1) or its ligand PD-L1, unleash the immune system's ability to recognize and destroy tumor cells [8]. While checkpoint inhibitors have shown clinical efficacy in some cancer types like leukemia [9], they are limited by factors such as primary resistance, acquired resistance, and the lack of response in a substantial proportion of patients suffering from ovarian cancer [10], and lung cancer [11]. Thus, alternative strategies are needed to overcome these limitations and improve the overall effectiveness of checkpoint inhibitor therapy.…”

Section: Introductionmentioning

confidence: 99%

Unlocking the potential of dCas9: Epigenetic targeting in cancer immunotherapy

2024

IJFMR

View full text Add to dashboard Cite

Cancer's profound medical challenge underscores the urgency for innovative solutions. Contemporary immunotherapy has formidable challenges dealing with immune evasion, complex tumor microenvironments (TME), and checkpoint inhibitors. Improvements to immunotherapy have been made through genome editing for which the Cas9 system is utilized, but its reliance on DNA repair mechanisms coupled with elevated off-target effects presents limitations. One alternative approach to gene editing is the modulation of gene expression using dCas9 and associated effectors. An advantage is dCas9's non-cleaving nature which reduces the chance of off-target effects and avoids permanent changes to the genome, offering enhanced safety as a gene modulation tool. We reviewed ongoing studies and clinical trials on immunotherapy, gene expression, and dCas9 to address whether gene modulation via dCas9 could be a viable solution to improve gene therapy. In (one/a few) studies found that dCas9's adoption decreases off-target effects, heightening its appeal for improving immunotherapy compared to traditional gene editing with Cas9. Therefore, integrating dCas9 in suppressing key target genes, dcas9 with effector domains or epigenetic modifiers could prove as a pivotal strategy, enabling precise gene regulation and epigenetic modification. Specifically, transcriptional activators like VP64 and repressors like KRAB exhibit the potential to modulate target genes when used with dcas9. Acknowledging limitations, such as mutations affecting gene regulation, this study underscores the transformative potential of dCas9-mediated epigenetic regulation in reshaping the landscape of cancer treatment and calls for further investigation to unlock its full therapeutic potential.

show abstract

Biosynthesis of copper oxide nanoparticles using Tecoma stans flower extract and its antibacterial, anticancer, and photocatalytic activities

Vasantharaj,

Sathiyavimal,

Bharathi

et al. 2024

Biocatalysis and Agricultural Biotechnology

View full text Add to dashboard Cite

Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions

Cited by 4 publications

References 77 publications

Immune Checkpoint Inhibitors: A Narrative Review on PD-1/PD-L1 Blockade Mechanism, Efficacy, and Safety Profile in Treating Malignancy

Immune Checkpoint Inhibitors: A Narrative Review on PD-1/PD-L1 Blockade Mechanism, Efficacy, and Safety Profile in Treating Malignancy

Unlocking the potential of dCas9: Epigenetic targeting in cancer immunotherapy

Biosynthesis of copper oxide nanoparticles using Tecoma stans flower extract and its antibacterial, anticancer, and photocatalytic activities

Contact Info

Product

Resources

About